gaboxadol: Clinical Trials

22 trials of gaboxadol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed, 3 terminated, 2 withdrawn. 14 Phase 3, 7 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 314Completed 11, Terminated 2, Withdrawn 1
Phase 27Completed 5, Terminated 1, Withdrawn 1
Phase 11Completed 1

Follow gaboxadol: new trials by email Literature Review of gaboxadol trials Research Report on gaboxadol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Placebo-Controlled, Single-Dose Challenge Study of Gaboxadol in Adult Males With Fragile X Syndrome (FXS)
Gaboxadol, Placebo - Fragile X Syndrome
Phase 2CompletedCraig Erickson102024-01-292026-09-30
Investigation of Sulindac (HLX-0201) and Gaboxadol (HLX-0206) in Male Fragile X Syndrome Patients Aged 13-40
Sulindac (HLX-0201), dose strength 1, Sulindac (HLX-0201), dose strength 2, Placebo - Fragile X Syndrome
Phase 2WithdrawnHealx Limited2022-05-252022-12-08
A Study of OV101 in Individuals With Angelman Syndrome (AS)
Gaboxadol, Placebo - Primary Disease or Condition Being Studied: Angelman Syndrome (AS)
Phase 3CompletedOvid Therapeutics Inc.1042019-09-092024-01-08
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
OV101 - Angelman Syndrome
Phase 3TerminatedHealx AI1412019-01-312025-07-18
A Study of OV101 in Individuals With Fragile X Syndrome
OV101 (gaboxadol) - Fragile X Syndrome (FXS)
Phase 2CompletedOvid Therapeutics Inc.362018-09-172024-01-23
Single Dose Pharmacokinetic (PK) Study
OV101 - Angelman Syndrome, Fragile X Syndrome
Phase 1CompletedOvid Therapeutics Inc.122017-04-032017-11-30
A Study in Adults and Adolescents With Angelman Syndrome (STARS)
OV101 Regimen 1, OV101 regimen 2, Placebo - Angelman Syndrome
Phase 2CompletedHealx AI882016-01-012025-08-03
Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder
Escitalopram placebo, Gaboxadol placebo, Escitalopram 20 mg - Major Depressive Disorder
Phase 2CompletedH. Lundbeck A/S4902008-11-012012-12-17
MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
MK0928, gaboxadol / Duration of Treatment 3 Weeks, Placebo / Duration of Treatment 3 Weeks - Primary Insomnia
Phase 2CompletedH. Lundbeck A/S5202005-11-012015-01-14
Sleep Laboratory Study of MK0928 in Adult Patients With Primary Insomnia (0928-041)(TERMINATED)
MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose), Placebo / Duration of Treatment: 2 days for screening period - Primary Insomnia
Phase 2TerminatedH. Lundbeck A/S502005-11-012015-01-14
An Investigational Study of MK0928 in Adult Outpatients With Insomnia (0928-014)(COMPLETED)
gaboxadol, Comparator: placebo (unspecified) - Insomnia
Phase 3CompletedH. Lundbeck A/S9002005-02-012015-01-14
Study of MK0928 in Healthy Adult Volunteers in a Model of Insomnia (0928-006)(COMPLETED)
gaboxadol - Insomnia
Phase 3CompletedH. Lundbeck A/S6632005-02-012015-01-14
An Investigational Drug Study in Healthy Adult Volunteers in a Model of Insomnia (0928-007)
MK0928, gaboxadol / Duration of Treatment: 10 months - Insomnia
Phase 3WithdrawnH. Lundbeck A/S2005-01-012015-01-14
Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)
MK0928, gaboxadol / Duration of Treatment - 6 weeks, Comparator: placebo / Duration of Treatment - 6 weeks - Primary Insomnia
Phase 3TerminatedH. Lundbeck A/S4652004-11-012015-01-14
Adult Primary Insomnia Polysomnographic Study (0928-004)(COMPLETED)
gaboxadol, Comparator: placebo (unspecified) - Primary Insomnia
Phase 3CompletedH. Lundbeck A/S4652004-11-012015-01-14
Efficacy and Safety of MK0928 for Insomnia in Adults (0928-003)(COMPLETED)
MK0928, gaboxadol / Duration of Treatment - 1 year, Comparator: placebo / Duration of Treatment -1 year - Insomnia
Phase 3CompletedH. Lundbeck A/S6002004-10-012015-01-14
Safety of MK0928 on Insomnia in the Elderly (0928-005)(COMPLETED)
MK0928, gaboxadol, Comparator: placebo - Insomnia
Phase 3CompletedH. Lundbeck A/S3202004-10-012016-11-17
A Prospective Open-Label Extension Study of Gaboxadol in Primary Insomnia
Gaboxadol - Primary Insomnia
Phase 3CompletedH. Lundbeck A/S2002004-07-012007-03-30
A Study of Gaboxadol in Primary Insomnia
Gaboxadol - Primary Insomnia
Phase 3CompletedH. Lundbeck A/S3202004-06-012007-03-30
A Study of Gaboxadol in Primary Insomnia
Gaboxadol - Primary Insomnia
Phase 3CompletedH. Lundbeck A/S5052004-04-012007-03-30

Showing 20 of 22. Sign in to see all of them.

Conditions studied

Sleep Initiation and Maintenance Disorders (14)  ·  Fragile X Syndrome (4)  ·  Angelman Syndrome (3)  ·  Depressive Disorder, Major (1)

Sponsors

H. Lundbeck A/S (15)  ·  Ovid Therapeutics Inc. (3)  ·  Healx AI (2)  ·  Craig Erickson (1)  ·  Healx Limited (1)

Countries

United States (7)  ·  Israel (3)  ·  Australia (2)  ·  Germany (2)  ·  Sweden (2)  ·  Austria (1)  ·  Netherlands (1)  ·  Russia (1)

Top investigators

Amit Rakhit, MD (1)  ·  Amit Rakhit, MD, MBA (1)  ·  Cragi A Erickson, MD (1)  ·  Elizabeth Berry-Kravis (1)

Results publications

PMID 20191935, PMID 31926466, PMID 22003345, PMID 22008735, PMID 33395098, PMID 33443117, PMID 34690787, PMID 37639777, PMID 42104256

NIH funding

2008 (1)